Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1184402.RAL93-XX4rpDBFrzbUmrS_Dj18LFdxo0168THU-qi0y4I130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1184402.RAL93-XX4rpDBFrzbUmrS_Dj18LFdxo0168THU-qi0y4I130_assertion type Assertion NP1184402.RAL93-XX4rpDBFrzbUmrS_Dj18LFdxo0168THU-qi0y4I130_head.
- NP1184402.RAL93-XX4rpDBFrzbUmrS_Dj18LFdxo0168THU-qi0y4I130_assertion wasGeneratedBy ECO_0000203 NP1184402.RAL93-XX4rpDBFrzbUmrS_Dj18LFdxo0168THU-qi0y4I130_provenance.
- NP1184402.RAL93-XX4rpDBFrzbUmrS_Dj18LFdxo0168THU-qi0y4I130_assertion wasDerivedFrom befree-2016 NP1184402.RAL93-XX4rpDBFrzbUmrS_Dj18LFdxo0168THU-qi0y4I130_provenance.
- NP1184402.RAL93-XX4rpDBFrzbUmrS_Dj18LFdxo0168THU-qi0y4I130_assertion SIO_000772 24849046 NP1184402.RAL93-XX4rpDBFrzbUmrS_Dj18LFdxo0168THU-qi0y4I130_provenance.
- NP1184402.RAL93-XX4rpDBFrzbUmrS_Dj18LFdxo0168THU-qi0y4I130_assertion evidence source_evidence_literature NP1184402.RAL93-XX4rpDBFrzbUmrS_Dj18LFdxo0168THU-qi0y4I130_provenance.
- NP1184402.RAL93-XX4rpDBFrzbUmrS_Dj18LFdxo0168THU-qi0y4I130_assertion description "[RAS mutation remains an important biomarker predicting response to anti-EGFR therapies and perhaps clinical outcomes after surgery for metastatic colorectal cancer, but new techniques including genomic signatures need to be validated to take into account the complexity of Ras activation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1184402.RAL93-XX4rpDBFrzbUmrS_Dj18LFdxo0168THU-qi0y4I130_provenance.